Deciphera Pharmaceuticals Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks.

9 brokers have issued 12-month price objectives for Deciphera Pharmaceuticals' shares. Their DCPH stock forecasts range from $6.00 to $70.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $26.57 in the next year. This suggests a possible upside of 100.4% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of the year. Since then, DCPH shares have increased by 35.7% and is now trading at $13.26.
View the best growth stocks for 2022 here.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.03. The company earned $29.22 million during the quarter, compared to analyst estimates of $27.17 million. Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative trailing twelve-month return on equity of 79.96%. Deciphera Pharmaceuticals's quarterly revenue was up 16.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.06) earnings per share.
View Deciphera Pharmaceuticals' earnings history.

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Deciphera Pharmaceuticals include Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Blueprint Medicines (BPMC), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), CureVac (CVAC), Indivior (INVVY), Pacira BioSciences (PCRX), Insmed (INSM), HUTCHMED (HCM) and ACADIA Pharmaceuticals (ACAD).
View all of DCPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $13.26.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $878.08 million and generates $96.15 million in revenue each year. The company earns $-299.96 million in net income (profit) each year or ($4.89) on an earnings per share basis.

Deciphera Pharmaceuticals employs 280 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for Deciphera Pharmaceuticals is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.